Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels.

Meijer D, van Moorselaar RJA, Vis AN, Bijnsdorp IV.

Cancers (Basel). 2019 Jul 7;11(7). pii: E953. doi: 10.3390/cancers11070953.

2.

Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.

Faisal FA, Sundi D, Pierorazio PM, Ball MW, Humphreys EB, Han M, Epstein JI, Partin AW, Carter HB, Bivalacqua TJ, Schaeffer EM, Ross AE.

BJU Int. 2014 Dec;114(6b):E120-E129. doi: 10.1111/bju.12771. Epub 2014 Aug 13.

3.

Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy.

Chao C, Jacobsen SJ, Xu L, Wallner LP, Porter KR, Williams SG.

BJU Int. 2013 May;111(6):954-62. doi: 10.1111/j.1464-410X.2012.11639.x. Epub 2013 Mar 6.

4.

Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ.

BJU Int. 2014 Nov;114(5):661-6. doi: 10.1111/bju.12720. Epub 2014 May 8.

5.

Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database.

Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ.

Cancer. 2010 Jul 15;116(14):3389-98. doi: 10.1002/cncr.25308.

6.

Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer.

Song C, Park S, Park J, Shim M, Kim A, Jeong IG, Hong JH, Kim CS, Ahn H.

Prostate. 2015 Feb;75(2):211-7. doi: 10.1002/pros.22907. Epub 2014 Oct 18.

PMID:
25327522
7.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
8.

Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.

Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, Cumberbatch M, De Santis M, Tilki D, Fanti S, Fossati N, Gillessen S, Grummet JP, Henry AM, Lardas M, Liew M, Rouvière O, Pecanka J, Mason MD, Schoots IG, van Der Kwast TH, van Der Poel HG, Wiegel T, Willemse PM, Yuan Y, Lam TB, Cornford P, Mottet N.

Eur Urol. 2019 Jun;75(6):967-987. doi: 10.1016/j.eururo.2018.10.011. Epub 2018 Oct 17. Review.

PMID:
30342843
9.

Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.

Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco FJ Jr, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW, Stephenson AJ.

Eur Urol. 2015 Jun;67(6):1160-1167. doi: 10.1016/j.eururo.2014.09.019. Epub 2014 Oct 6.

10.

Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA(TM) , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study.

Lepor H, Cheli CD, Thiel RP, Taneja SS, Laze J, Chan DW, Sokoll LJ, Mangold L, Partin AW.

BJU Int. 2012 Jun;109(12):1770-5. doi: 10.1111/j.1464-410X.2011.10568.x. Epub 2011 Oct 12.

11.

[-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report.

De Luca S, Passera R, Sottile A, Fiori C, Scarpa RM, Porpiglia F.

BMC Urol. 2016 Mar 24;16:14. doi: 10.1186/s12894-016-0131-0.

12.

Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence.

Inoue H, Nishimura K, Yamaguchi S, Nonomura N, Hara T.

Int J Clin Oncol. 2015 Feb;20(1):171-5. doi: 10.1007/s10147-014-0681-7. Epub 2014 Mar 21.

PMID:
24652165
13.

The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.

Eminaga O, Hinkelammert R, Titze U, Abbas M, Eltze E, Bettendorf O, Semjonow A.

Urol Oncol. 2014 Jan;32(1):32.e17-25. doi: 10.1016/j.urolonc.2012.11.021. Epub 2013 Feb 19.

PMID:
23434425
14.

Prediction of Biochemical Recurrence Following Radiotherapy among Patients with Persistent PSA after Radical Prostatectomy: A Single-Center Experience.

Xiang C, Liu X, Chen S, Wang P.

Urol Int. 2018;101(1):47-55. doi: 10.1159/000488536. Epub 2018 Apr 6.

PMID:
29627830
15.

A risk-adjusted definition of biochemical recurrence after radical prostatectomy.

Morgan TM, Meng MV, Cooperberg MR, Cowan JE, Weinberg V, Carroll PR, Lin DW.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):174-9. doi: 10.1038/pcan.2014.5. Epub 2014 Mar 11.

PMID:
24614692
16.

Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer.

Hamada R, Nakashima J, Ohori M, Ohno Y, Komori O, Yoshioka K, Tachibana M.

Int J Clin Oncol. 2016 Jun;21(3):595-600. doi: 10.1007/s10147-015-0923-3. Epub 2015 Nov 19. Erratum in: Int J Clin Oncol. 2016 Jun;21(3):601.

PMID:
26585896
17.

Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.

Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A.

Eur Urol. 2016 Apr;69(4):728-733. doi: 10.1016/j.eururo.2015.10.009. Epub 2015 Oct 21.

PMID:
26497924
18.

68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.

Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG.

J Nucl Med. 2018 Feb;59(2):230-237. doi: 10.2967/jnumed.117.201749. Epub 2017 Nov 9.

19.

Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.

Koie T, Mitsuzuka K, Yoneyama T, Narita S, Kawamura S, Kaiho Y, Tsuchiya N, Tochigi T, Habuchi T, Arai Y, Ohyama C, Yoneyama T, Tobisawa Y.

Int J Clin Oncol. 2015 Feb;20(1):176-81. doi: 10.1007/s10147-014-0696-0. Epub 2014 Apr 29.

PMID:
24771079
20.

68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy.

Farolfi A, Ceci F, Castellucci P, Graziani T, Siepe G, Lambertini A, Schiavina R, Lodi F, Morganti AG, Fanti S.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):11-19. doi: 10.1007/s00259-018-4066-4. Epub 2018 Jun 15.

PMID:
29905907

Supplemental Content

Support Center